| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| NAGENiagen Bioscience Inc | 503.58M | 6.31 | 57.36 | 19.18% | 16.38% | 28.91% | 2.37% | 0.06 |
| BTXBlackRock Technology and Private Equity Term Trust | 808.8M | 6.93 | 40.76 | -81.13% | 87.75% | 1.87% | 34.27% | |
| HALOHalozyme Therapeutics, Inc. | 8.45B | 71.82 | 20.94 | 22.44% | 47.91% | 118.17% | 5.55% | 4.14 |
| RPRXRoyalty Pharma plc | 16.97B | 39.72 | 20.80 | -3.86% | 32.55% | 7.95% | 16.32% | 0.74 |
| REGNRegeneron Pharmaceuticals, Inc. | 76.63B | 741.92 | 19.35 | 8.27% | 32.13% | 14.79% | 4.78% | 0.09 |
| GMABGenmab A/S | 20.85B | 33.85 | 2.79 | 30.67% | 46.8% | 114.25% | 36.37% | 0.03 |
| DNAGinkgo Bioworks Holdings, Inc. | 464.86M | 9.58 | -0.91 | -9.71% | -188% | -60.66% | 0.65 | |
| PRMEPrime Medicine, Inc. | 720.24M | 3.99 | -2.42 | -33.02% | -121.95% | 0.27 |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 71.91M | 108.97M | 141.1M | 251.45M | 120.28M | 163.56M | 241.54M | 196.25M | 131.31M | 167.13M |
| Revenue Growth % | 0.11% | 0.52% | 0.29% | 0.78% | -0.52% | 0.36% | 0.48% | -0.19% | -0.33% | 0.27% |
| Cost of Goods Sold | 5.81M | 5.57M | 5.37M | 6.34M | 11.35M | 30.42M | 62.18M | 52.83M | 35.05M | 11.07M |
| COGS % of Revenue | 0.08% | 0.05% | 0.04% | 0.03% | 0.09% | 0.19% | 0.26% | 0.27% | 0.27% | 0.07% |
| Gross Profit | 66.11M | 103.4M | 135.74M | 245.12M | 108.94M | 133.14M | 179.37M | 143.42M | 96.27M | 156.06M |
| Gross Margin % | 0.92% | 0.95% | 0.96% | 0.97% | 0.91% | 0.81% | 0.74% | 0.73% | 0.73% | 0.93% |
| Gross Profit Growth % | 0.19% | 0.56% | 0.31% | 0.81% | -0.56% | 0.22% | 0.35% | -0.2% | -0.33% | 0.62% |
| Operating Expenses | 37.76M | 58.48M | 67.66M | 81.39M | -698.14M | 95.64M | 75.52M | 140.38M | 84.32M | 178.66M |
| OpEx % of Revenue | 0.53% | 0.54% | 0.48% | 0.32% | -5.8% | 0.58% | 0.31% | 0.72% | 0.64% | 1.07% |
| Selling, General & Admin | 24.38M | 26.62M | 28.65M | 37.73M | 41.88M | 60.01M | 46.79M | 70.06M | 52.79M | 78.65M |
| SG&A % of Revenue | 0.34% | 0.24% | 0.2% | 0.15% | 0.35% | 0.37% | 0.19% | 0.36% | 0.4% | 0.47% |
| Research & Development | 13.38M | 21.22M | 26.89M | 27.86M | 55.91M | 40.5M | 32.1M | 36.08M | 24.54M | 21.43M |
| R&D % of Revenue | 0.19% | 0.19% | 0.19% | 0.11% | 0.46% | 0.25% | 0.13% | 0.18% | 0.19% | 0.13% |
| Other Operating Expenses | 0 | 10.64M | 12.12M | 15.79M | -795.93M | -4.87M | -3.38M | 34.24M | 7M | 78.59M |
| Operating Income | 27.33M | 43.88M | 68.08M | 163.73M | 807.08M | 37.5M | 103.85M | 3.04M | 11.94M | -22.61M |
| Operating Margin % | 0.38% | 0.4% | 0.48% | 0.65% | 6.71% | 0.23% | 0.43% | 0.02% | 0.09% | -0.14% |
| Operating Income Growth % | 0.39% | 0.61% | 0.55% | 1.41% | 3.93% | -0.95% | 1.77% | -0.97% | 2.93% | -2.89% |
| EBITDA | 29.96M | 55.17M | 80.6M | 180.42M | 850.81M | 65.47M | 154.8M | 46.43M | 48.46M | 12.63M |
| EBITDA Margin % | 0.42% | 0.51% | 0.57% | 0.72% | 7.07% | 0.4% | 0.64% | 0.24% | 0.37% | 0.08% |
| EBITDA Growth % | 0.34% | 0.84% | 0.46% | 1.24% | 3.72% | -0.92% | 1.36% | -0.7% | 0.04% | -0.74% |
| D&A (Non-Cash Add-back) | 2.63M | 11.29M | 12.52M | 16.69M | 43.73M | 27.97M | 50.95M | 43.39M | 36.52M | 35.24M |
| EBIT | 27.33M | 20.8M | 68.63M | 221.61M | 832.38M | 28.71M | 91.82M | 37.81M | 64.32M | 5.55M |
| Net Interest Income | -11.8M | -12.18M | -11.4M | -34.28M | -7.32M | -19.34M | -18.73M | 247K | 7.05M | 5.02M |
| Interest Income | 0 | 0 | 0 | 14M | 28.43M | 8.08M | 886K | 2.05M | 7.71M | 8.05M |
| Interest Expense | 11.8M | 12.18M | 11.4M | 48.28M | 35.74M | 27.41M | 19.62M | 1.8M | 656K | 3.04M |
| Other Income/Expense | 8M | -35.92M | -10.85M | 9.6M | -10.44M | -36.21M | -31.65M | 32.97M | 51.72M | 25.12M |
| Pretax Income | 35.33M | 7.96M | 57.23M | 173.33M | 796.64M | 1.29M | 72.2M | 36.01M | 63.66M | 2.52M |
| Pretax Margin % | 0.49% | 0.07% | 0.41% | 0.69% | 6.62% | 0.01% | 0.3% | 0.18% | 0.48% | 0.02% |
| Income Tax | -219.6M | 10.33M | 44.67M | 30.01M | 167.34M | -5.31M | -4.15M | 41.23M | 9.84M | 6.55M |
| Effective Tax Rate % | 7.28% | -0.21% | 0.22% | 0.83% | 0.79% | -2.31% | 0.79% | -0.93% | 0.82% | -1.6% |
| Net Income | 257.31M | -1.64M | 12.56M | 143.32M | 629.3M | -2.98M | 57.14M | -33.36M | 52.15M | -4.03M |
| Net Margin % | 3.58% | -0.02% | 0.09% | 0.57% | 5.23% | -0.02% | 0.24% | -0.17% | 0.4% | -0.02% |
| Net Income Growth % | 20.4% | -1.01% | 8.67% | 10.41% | 3.39% | -1% | 20.14% | -1.58% | 2.56% | -1.08% |
| Net Income (Continuing) | 227.44M | -2.37M | 12.56M | 143.32M | 629.3M | 6.6M | 76.35M | -5.22M | 53.82M | -4.03M |
| Discontinued Operations | 0 | 731K | 0 | 0 | 0 | -9.58M | -19.21M | -28.14M | -1.67M | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | 12.12 | -0.08 | 0.53 | 5.96 | 31.85 | -0.18 | 3.34 | -1.98 | 2.94 | -0.22 |
| EPS Growth % | 20.64% | -1.01% | 7.75% | 10.25% | 4.34% | -1.01% | 19.56% | -1.59% | 2.48% | -1.07% |
| EPS (Basic) | 13.00 | -0.08 | 0.60 | 5.96 | 33.13 | -0.18 | 3.46 | -1.98 | 3.02 | -0.22 |
| Diluted Shares Outstanding | 21.23M | 20.83M | 23.48M | 24.07M | 19.76M | 16.18M | 17.25M | 16.87M | 17.76M | 18.29M |
| Basic Shares Outstanding | 19.79M | 20.83M | 21.03M | 24.05M | 19M | 16.18M | 16.63M | 16.87M | 17.3M | 18.29M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 215.57M | 163.05M | 237.02M | 870.54M | 1.12B | 500.56M | 464.75M | 263.6M | 237.43M | 331.56M |
| Cash & Short-Term Investments | 200.22M | 141.05M | 201.66M | 764.57M | 1.07B | 411.19M | 341.11M | 211.87M | 170.31M | 256.17M |
| Cash Only | 200.22M | 141.05M | 201.66M | 718.38M | 71.54M | 47.62M | 19.52M | 45.01M | 22.95M | 72.31M |
| Short-Term Investments | 0 | 0 | 0 | 46.19M | 998.32M | 363.57M | 321.59M | 166.86M | 147.35M | 183.86M |
| Accounts Receivable | 11.68M | 18.22M | 25.6M | 55.85M | 41.75M | 59.06M | 91.65M | 35.04M | 39.31M | 42.45M |
| Days Sales Outstanding | 59.3 | 61.02 | 66.21 | 81.07 | 126.69 | 131.81 | 138.49 | 65.17 | 109.27 | 92.7 |
| Inventory | 1.63M | 1.92M | 4.37M | 7.12M | 7.3M | 26.49M | 27.33M | 13.29M | 23.97M | 14.11M |
| Days Inventory Outstanding | 102.64 | 125.99 | 297.46 | 410.33 | 234.69 | 317.82 | 160.42 | 91.85 | 249.61 | 465.2 |
| Other Current Assets | 0 | 0 | 5.39M | 89.19M | 4.73M | 3.82M | 4.67M | 2.27M | 2.66M | 16.9M |
| Total Non-Current Assets | 318.36M | 438.53M | 434M | 390.26M | 371.27M | 861.73M | 832.84M | 499.07M | 549.79M | 610.22M |
| Property, Plant & Equipment | 372K | 1.82M | 4.21M | 5.37M | 17.62M | 37.17M | 32.6M | 27.49M | 25.06M | 24.81M |
| Fixed Asset Turnover | 193.32x | 59.91x | 33.50x | 46.81x | 6.83x | 4.40x | 7.41x | 7.14x | 5.24x | 6.74x |
| Goodwill | 60.59M | 276.91M | 314.54M | 306.44M | 95.23M | 189.66M | 105.67M | 105.67M | 103.37M | 105.25M |
| Intangible Assets | 8.55M | 25.82M | 19.53M | 31.46M | 230.54M | 606.31M | 386.8M | 352.64M | 299.61M | 266.65M |
| Long-Term Investments | 29.73M | 8.35M | 6.44M | 601.22M | 0 | 0 | 0 | 3M | 111.61M | 10.91M |
| Other Non-Current Assets | 2.55M | 1.74M | 4.86M | -600.75M | 2.27M | 4.27M | 272.03M | 1.74M | 9.92M | 202.53M |
| Total Assets | 533.93M | 601.59M | 671.02M | 1.26B | 1.49B | 1.36B | 1.3B | 762.67M | 787.22M | 941.77M |
| Asset Turnover | 0.13x | 0.18x | 0.21x | 0.20x | 0.08x | 0.12x | 0.19x | 0.26x | 0.17x | 0.18x |
| Asset Growth % | 1.07% | 0.13% | 0.12% | 0.88% | 0.19% | -0.09% | -0.05% | -0.41% | 0.03% | 0.2% |
| Total Current Liabilities | 20.84M | 227.13M | 238.87M | 82.25M | 17M | 100.11M | 41.66M | 98.81M | 16.78M | 37.11M |
| Accounts Payable | 4.08M | 2.73M | 2.26M | 4.18M | 2.42M | 3.78M | 8.4M | 5.31M | 2.43M | 5.23M |
| Days Payables Outstanding | 256.64 | 179.13 | 153.66 | 240.93 | 77.84 | 45.4 | 49.33 | 36.67 | 25.27 | 172.48 |
| Short-Term Debt | 201.99M | 212.91M | 224.53M | 26.43M | 0 | 0 | 0 | 76.69M | 0 | 0 |
| Deferred Revenue (Current) | -934K | 0 | 173K | 1000K | 1000K | 1000K | 654K | 976K | 1000K | 1000K |
| Other Current Liabilities | 15.04M | 5.09M | 1.41M | 44.3M | 7.62M | 49.38M | 22.57M | 6.26M | 4.94M | -3.2M |
| Current Ratio | 10.35x | 0.72x | 0.99x | 10.58x | 66.09x | 5.00x | 11.15x | 2.67x | 14.15x | 8.93x |
| Quick Ratio | 10.27x | 0.71x | 0.97x | 10.50x | 65.66x | 4.74x | 10.50x | 2.53x | 12.72x | 8.55x |
| Cash Conversion Cycle | -94.7 | 7.89 | 210.01 | 250.47 | 283.53 | 404.22 | 249.57 | 120.35 | 333.61 | 385.42 |
| Total Non-Current Liabilities | 208.7M | 3.6M | 13.51M | 617.64M | 710.68M | 552.65M | 434.77M | 66.37M | 69.52M | 74.22M |
| Long-Term Debt | 205.37M | 29.56M | 18.86M | 609.86M | 638.96M | 442.29M | 320.72M | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 9.97M | 5.64M | 2.26M | 10.34M | 5.75M | 5.82M |
| Deferred Tax Liabilities | 0 | -357K | -22.38M | 51.97M | 32.94M | 64.6M | 30.86M | 30.61M | 31.62M | 32.52M |
| Other Non-Current Liabilities | 3.33M | -25.96M | -8.88M | 7.78M | 28.82M | 40.12M | 80.94M | 25.38M | 17M | 35.88M |
| Total Liabilities | 229.54M | 230.73M | 252.37M | 699.89M | 727.68M | 652.76M | 476.43M | 165.18M | 86.3M | 111.33M |
| Total Debt | 205.37M | 212.91M | 224.53M | 636.3M | 650.18M | 456.41M | 324.39M | 87.75M | 6.17M | 7.11M |
| Net Debt | 5.15M | 71.86M | 22.87M | -82.08M | 578.64M | 408.8M | 304.86M | 42.74M | -16.79M | -65.2M |
| Debt / Equity | 0.67x | 0.57x | 0.54x | 1.13x | 0.85x | 0.64x | 0.40x | 0.15x | 0.01x | 0.01x |
| Debt / EBITDA | 6.86x | 3.86x | 2.79x | 3.53x | 0.76x | 6.97x | 2.10x | 1.89x | 0.13x | 0.56x |
| Net Debt / EBITDA | 0.17x | 1.30x | 0.28x | -0.45x | 0.68x | 6.24x | 1.97x | 0.92x | -0.35x | -5.16x |
| Interest Coverage | 2.32x | 3.60x | 5.97x | 3.39x | 22.58x | 1.37x | 5.29x | 1.69x | 18.20x | -7.44x |
| Total Equity | 304.39M | 370.85M | 418.65M | 560.91M | 767.23M | 709.52M | 821.16M | 597.49M | 700.91M | 830.44M |
| Equity Growth % | 11.47% | 0.22% | 0.13% | 0.34% | 0.37% | -0.08% | 0.16% | -0.27% | 0.17% | 0.18% |
| Book Value per Share | 14.34 | 17.80 | 17.83 | 23.31 | 38.83 | 43.84 | 47.61 | 35.42 | 39.47 | 45.40 |
| Total Shareholders' Equity | 304.39M | 370.85M | 418.65M | 560.91M | 767.23M | 709.52M | 821.16M | 597.49M | 700.91M | 830.44M |
| Common Stock | 20K | 21K | 21K | 21K | 17K | 16K | 17K | 17K | 18K | 20K |
| Retained Earnings | -402.01M | -431.13M | -400.92M | -229.2M | 400.11M | 391.95M | 449.09M | 450.86M | 503.02M | 498.98M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 4.9M | 2.74M | 2.49M | -1.02M | -216K | -801K | -917K | -984K | -817K | -5.94M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | 41.73M | 63M | 93.57M | 194.06M | -29.34M | 54.59M | 78.8M | 137.85M | 49.58M | 97.05M |
| Operating CF Margin % | 0.58% | 0.58% | 0.66% | 0.77% | -0.24% | 0.33% | 0.33% | 0.7% | 0.38% | 0.58% |
| Operating CF Growth % | 1.03% | 0.51% | 0.49% | 1.07% | -1.15% | 2.86% | 0.44% | 0.75% | -0.64% | 0.96% |
| Net Income | 254.93M | -2.37M | 12.56M | 143.32M | 629.3M | -2.98M | 57.14M | -33.36M | 52.15M | -4.03M |
| Depreciation & Amortization | 2.63M | 11.29M | 11.71M | 14.72M | 43.73M | 27.97M | 50.95M | 51.37M | 36.52M | 35.24M |
| Stock-Based Compensation | 12.46M | 18.89M | 24.91M | 20.85M | 24.52M | 30.73M | 38.78M | 60.28M | 25.74M | 41.09M |
| Deferred Taxes | -219.61M | 10.7M | 44.52M | 29.74M | 74.83M | -19.05M | -8.62M | 20.72M | 11.7M | -15.8M |
| Other Non-Cash Items | -9.49M | 35.11M | 11.3M | 24.29M | -797.5M | 28M | -7.29M | -26.84M | -42.13M | 21.2M |
| Working Capital Changes | 821K | -10.62M | -11.44M | -38.85M | -4.21M | -10.06M | -52.16M | 65.68M | -34.4M | 19.36M |
| Change in Receivables | 6.49M | -8.53M | -8.36M | -29.54M | 25.46M | -26.06M | -28.62M | 55.32M | -2.6M | -6.46M |
| Change in Inventory | -401K | -244K | -843K | -2.56M | -2.06M | -17.8M | -427K | 12.06M | -10.87M | 9.62M |
| Change in Payables | -4.03M | -2.37M | -1.71M | -4.54M | -18.05M | -1.25M | -1.17M | -3.34M | -4.7M | 0 |
| Cash from Investing | -112.86M | -143.19M | -84.18M | -423.27M | 466.92M | 231.65M | 30.52M | 163.62M | -11.68M | -143.66M |
| Capital Expenditures | -10.86M | -28.32M | -7.15M | -11.89M | -2.55M | -4.46M | -8.76M | -17.92M | -3.52M | -1.82M |
| CapEx % of Revenue | 0.15% | 0.26% | 0.05% | 0.05% | 0.02% | 0.03% | 0.04% | 0.09% | 0.03% | 0.01% |
| Acquisitions | - | - | - | - | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | -15.99M | 300K | 7.25M | 3.91M | 808.13M | 3.26M | -1.22M | -868K | -49.91M | -12.89M |
| Cash from Financing | 8.36M | 1.51M | -7.52M | 328.58M | -485.17M | -310.55M | -137.76M | -275.99M | -59.95M | 97.14M |
| Debt Issued (Net) | - | - | - | - | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - | - | - | - | - |
| Other Financing | 8.85M | -999K | -5.56M | -77.11M | -383K | -789K | -7.07M | -6.75M | 16.95M | 60.03M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | 30.86M | 34.68M | 86.41M | 182.17M | -31.89M | 50.13M | 70.04M | 119.93M | -4.27M | 77.41M |
| FCF Margin % | 0.43% | 0.32% | 0.61% | 0.72% | -0.27% | 0.31% | 0.29% | 0.61% | -0.03% | 0.46% |
| FCF Growth % | 0.92% | 0.12% | 1.49% | 1.11% | -1.18% | 2.57% | 0.4% | 0.71% | -1.04% | 19.12% |
| FCF per Share | 1.45 | 1.66 | 3.68 | 7.57 | -1.61 | 3.10 | 4.06 | 7.11 | -0.24 | 4.23 |
| FCF Conversion (FCF/Net Income) | 0.16x | -38.51x | 7.45x | 1.35x | -0.05x | -18.29x | 1.38x | -4.13x | 0.95x | -24.07x |
| Interest Paid | 1.82M | 1.84M | 1.84M | 1.51M | 5.83M | 4.46M | 3.03M | 1.43M | 288K | 263K |
| Taxes Paid | 28K | 38K | 157K | 341K | 103.82M | 2.13M | 3.72M | 11.64M | 8.77M | 19.21M |
| Metric | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | 156.51% | -0.48% | 3.18% | 29.26% | 94.76% | -0.4% | 7.47% | -4.7% | 8.03% | -0.53% |
| Return on Invested Capital (ROIC) | 11.3% | 8.75% | 11.55% | 26.68% | 66.35% | 2.28% | 6.94% | 0.26% | 1.35% | -2.34% |
| Gross Margin | 91.93% | 94.89% | 96.2% | 97.48% | 90.57% | 81.4% | 74.26% | 73.08% | 73.31% | 93.37% |
| Net Margin | 357.8% | -1.5% | 8.9% | 57% | 523.19% | -1.82% | 23.66% | -17% | 39.72% | -2.41% |
| Debt / Equity | 0.67x | 0.57x | 0.54x | 1.13x | 0.85x | 0.64x | 0.40x | 0.15x | 0.01x | 0.01x |
| Interest Coverage | 2.32x | 3.60x | 5.97x | 3.39x | 22.58x | 1.37x | 5.29x | 1.69x | 18.20x | -7.44x |
| FCF Conversion | 0.16x | -38.51x | 7.45x | 1.35x | -0.05x | -18.29x | 1.38x | -4.13x | 0.95x | -24.07x |
| Revenue Growth | 11.43% | 51.53% | 29.48% | 78.21% | -52.17% | 35.98% | 47.68% | -18.75% | -33.09% | 27.28% |
| 2012 | 2013 | 2014 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Royalty | - | - | - | - | 46.98M | - | 48.93M | 72.53M | 83.91M | 108.77M |
| Royalty Growth | - | - | - | - | - | - | - | 48.24% | 15.69% | 29.63% |
| Intangible Royalty Assets | - | - | - | - | - | - | - | - | - | 95.33M |
| Intangible Royalty Assets Growth | - | - | - | - | - | - | - | - | - | - |
| Royalty, Kyprolis | - | - | - | - | 25.05M | - | 27.47M | 30.12M | 35.64M | 38.38M |
| Royalty, Kyprolis Growth | - | - | - | - | - | - | - | 9.62% | 18.34% | 7.68% |
| Material Sales, Captisol, Core | - | - | - | - | - | - | - | 16.43M | 28.37M | 30.88M |
| Material Sales, Captisol, Core Growth | - | - | - | - | - | - | - | - | 72.69% | 8.85% |
| Material Sales, Captisol | - | - | - | 29.12M | 31.49M | 109.96M | 164.25M | 104.5M | 28.37M | 30.88M |
| Material Sales, Captisol Growth | - | - | - | - | 8.12% | 249.20% | 49.37% | -36.38% | -72.85% | 8.85% |
| Contract Revenue | - | - | - | - | - | 42.66M | 63.96M | 19.22M | 19.03M | 27.48M |
| Contract Revenue Growth | - | - | - | - | - | - | 49.91% | -69.94% | -0.99% | 44.37% |
| Service | - | - | - | - | - | 21.8M | 23.71M | 1.12M | 615K | 25.53M |
| Service Growth | - | - | - | - | - | - | 8.76% | -95.29% | -44.94% | 4051.71% |
| Financial Royalty Assets | - | - | - | - | - | - | - | - | - | 13.44M |
| Financial Royalty Assets Growth | - | - | - | - | - | - | - | - | - | - |
| Royalty, Other | - | - | - | - | 2.57M | - | 11.38M | 7.63M | 13.48M | 8.95M |
| Royalty, Other Growth | - | - | - | - | - | - | - | -32.90% | 76.56% | -33.63% |
| Royalty, Evomela | - | - | - | - | 5.17M | - | 10.08M | 10.2M | 10.21M | 8.68M |
| Royalty, Evomela Growth | - | - | - | - | - | - | - | 1.17% | 0.15% | -15.00% |
| License Fees | - | - | - | 78.19M | 6.2M | 4.38M | 5.08M | 2.85M | 217K | 1.94M |
| License Fees Growth | - | - | - | - | -92.07% | -29.38% | 16.13% | -43.96% | -92.38% | 795.85% |
| Milestone | - | - | - | 6.58M | 23.45M | 11.52M | 28.75M | 9.15M | 16.8M | - |
| Milestone Growth | - | - | - | - | 256.56% | -50.89% | 149.64% | -68.17% | 83.61% | - |
| License Fees, Milestones, and Other Product, Other | - | - | - | 9M | 12.17M | 4.97M | 6.41M | 6.11M | 1.4M | - |
| License Fees, Milestones, and Other Product, Other Growth | - | - | - | - | 35.16% | -59.18% | 29.09% | -4.76% | -77.08% | - |
| Material Sales, Captisol, COVID | - | - | - | - | - | - | - | 88.07M | - | - |
| Material Sales, Captisol, COVID Growth | - | - | - | - | - | - | - | - | - | - |
| License Fees, Milestones, and Product, Other | - | - | - | 93.77M | 41.82M | - | - | - | - | - |
| License Fees, Milestones, and Product, Other Growth | - | - | - | - | -55.41% | - | - | - | - | - |
| Royalty, Promacta | - | - | - | - | 14.19M | - | - | - | - | - |
| Royalty, Promacta Growth | - | - | - | - | - | - | - | - | - | - |
| Cydex Pharmaceuticals, Inc | 11.81M | 27.54M | 37.36M | - | - | - | - | - | - | - |
| Cydex Pharmaceuticals, Inc Growth | - | 133.25% | 35.69% | - | - | - | - | - | - | - |
| Ligand | 19.58M | 21.44M | 27.17M | - | - | - | - | - | - | - |
| Ligand Growth | - | 9.47% | 26.77% | - | - | - | - | - | - | - |
Ligand Pharmaceuticals Incorporated (LGND) reported $251.2M in revenue for fiscal year 2024. This represents a 736% increase from $30.0M in 2011.
Ligand Pharmaceuticals Incorporated (LGND) grew revenue by 27.3% over the past year. This is strong growth.
Yes, Ligand Pharmaceuticals Incorporated (LGND) is profitable, generating $48.6M in net income for fiscal year 2024 (-2.4% net margin).
Ligand Pharmaceuticals Incorporated (LGND) has a return on equity (ROE) of -0.5%. Negative ROE indicates the company is unprofitable.
Ligand Pharmaceuticals Incorporated (LGND) generated $30.8M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.